Compound index

Amylin Receptor Agonists

Cagrilintide

Late-stage human trialsInvestigational

Last reviewed: 2026-11-19

Overview

A long-acting amylin analog studied in controlled human trials.

Regulatory status

No FDA-approved human medicine for this exact identity was established in this review. Investigational research is not approval.

    Status as of 2026-11-19. Regulations change. Check FDA.gov for current information.

    WADA prohibited status: current list and context

    Evidence at a glance

    Large trials investigate this molecule alone and in combinations; results for a combination cannot be attributed entirely to cagrilintide.

    Key sources

    Primary-reference and editorial check: November 19, 2026. Not an exhaustive clinical review; exact formulations and populations matter.

    Related glossary terms